After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Zevra Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Zevra Therapeutics Inc is $460.87M. A total of 1.42 million shares were traded on the day, compared to an average of 1.24M shares.
In the most recent transaction, Bode John B bought 5,000 shares of ZVRA for 9.16 per share on Aug 19 ’25. After the transaction, the Director now owns 45,000 company shares. In a previous transaction on Jun 26 ’25, Thompson Rahsaan sold 24,000 shares at 9.21 per share. ZVRA shares that Chief Legal & Compliance owns now total 42,666.
Among the insiders who bought shares, RAHSAAN THOMPSON acquired of 24,000 shares on Jun 26 ’25 at a per-share price of $9.33. In another insider transaction, Watton Corey Michael bought 300 shares at $7.84 per share on Mar 28 ’25. Company shares held by the Director now total 1,800.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ZVRA has a high of $13.16 and a low of $6.19.
As of this writing, ZVRA has an earnings estimate of -$0.02 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of $0.01 per share and a lower estimate of -$0.04. The company reported an EPS of -$0.69 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ZVRA’s latest balance sheet shows that the firm has $112.35M in Cash & Short Term Investments as of fiscal 2021. There were $1.61M in debt and $4.23M in liabilities at the time. Its Book Value Per Share was $2.13, while its Total Shareholder’s Equity was $127.12M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZVRA is Buy with a score of 4.78.
